AI-generated summary
The authors systematically reviewed four studies on the cost-effectiveness of photobiomodulation therapy for cancer treatment toxicities, covering breast cancer-related lymphedema and oral mucositis. They report that better outcomes were associated with photobiomodulation and give cost figures per case prevented or per percentage point reduction. The authors conclude there is only limited evidence that the therapy is cost-effective for these specific toxicities.
- Studies included
- 4
- Who or what was studied
- Cancer patients receiving chemotherapy or radiotherapy, including those with breast cancer-related lymphedema and oral mucositis
- Limits stated in the abstract
- The authors state that the evidence is limited and that studies may have underreported benefits due to a lack of comprehensive cost evaluation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Systematic review, Photobiomodulation therapy, Oral mucositis, Meta-analysis, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.